nach oben

Erschienen in:

08.08.2023 | Research

PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort

verfasst von: Ryohei Otani, Masachika Ikegami, Ryoji Yamada, Hirohisa Yajima, Shinji Kawamura, Sakura Shimizu, Shota Tanaka, Shunsaku Takayanagi, Hirokazu Takami, Tatsuro Yamaguchi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glioblastoma (GBM) is the most common type of primary malignant brain tumor and has a poor prognosis. Identifying novel targets and stratification strategies is urgently needed to improve patient survival. The present study aimed to identify clinically relevant genomic alterations in IDH-wildtype GBM using data from comprehensive genomic profiling (CGP) assays performed nationwide in Japan.

Methods

The CGP assay results of 392 IDH-wildtype GBM cases performed between October 2019 and February 2023 obtained from the Center for Cancer Genomics and Advanced Therapeutics were retrospectively analyzed.

Results

The median patient age was 52.5 years, and 207 patients (53%) were male. In the 286 patients for whom survival information was available, a protein-tyrosine phosphatase non-receptor type 11 (PTPN11) variant detected in 20 patients (6.8%) was extracted as the gene associated with significantly shorter overall survival (p = 0.002). Multivariate analysis demonstrated that the PTPN11 variant and poor performance status were independent prognostic indicators. In contrast, no prognostic impact was observed in the cohort in The Cancer Genome Atlas data. The discrepancy in the prognostic impact of the PTPN11 variant from these two pools might have resulted from differences in the biases affecting the survival of patients who underwent a CGP assay, including left-truncation and right-censored bias. However, survival simulation done to adjust for these biases showed that the prognostic impact of the PTPN11 variant was also significant.

Conclusions

The PTPN11 variant was a negative prognostic indicator of IDH-wildtype GBM in the patient cohort with the CGP assay.

Nur mit Berechtigung zugänglich

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:829–848. https://doi.org/10.1007/s00401-015-1432-1CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRefPubMed

Yoshii Y, Okazaki S, Takeda M (2021) Current status of next-generation sequencing-based cancer genome profiling tests in japan and prospects for liquid biopsy. Life. https://doi.org/10.3390/life11080796CrossRefPubMedPubMedCentral

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T (2019) Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 110:1480–1490. https://doi.org/10.1111/cas.13969CrossRefPubMedPubMedCentral

Mukai Y, Ueno H (2021) Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci 112:970–977. https://doi.org/10.1111/cas.14754CrossRefPubMedPubMedCentral

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS, Consortium APG (2022) Implications of selection bias due to delayed study entry in clinical genomic studies. JAMA Oncol 8:287–291. https://doi.org/10.1001/jamaoncol.2021.5153CrossRefPubMedPubMedCentral

Tamura T, Ikegami M, Kanemasa Y, Yomota M, Furusawa A, Otani R, Saita C, Yonese I, Onishi T, Kobayashi H, Akiyama T, Shimoyama T, Aruga T, Yamaguchi T (2023) Selection bias due to delayed comprehensive genomic profiling in Japan. Cancer Sci 114:1015–1025. https://doi.org/10.1111/cas.15651CrossRefPubMed

Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816–8820. https://doi.org/10.1158/0008-5472.CAN-04-1923CrossRefPubMed

Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465–468. https://doi.org/10.1038/ng772CrossRefPubMed

10.

Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441–450. https://doi.org/10.1016/s0092-8674(00)80938-1CrossRefPubMed

11.

Gelb BD, Tartaglia M (2006) Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. https://doi.org/10.1093/hmg/ddl197CrossRefPubMed

12.

Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G, Ohh M (2015) Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun 6:8859. https://doi.org/10.1038/ncomms9859CrossRefPubMed

13.

Sang Y, Hou Y, Cheng R, Zheng L, Alvarez AA, Hu B, Cheng SY, Zhang W, Li Y, Feng H (2019) Targeting PDGFRalpha-activated glioblastoma through specific inhibition of SHP-2-mediated signaling. Neuro Oncol 21:1423–1435. https://doi.org/10.1093/neuonc/noz107CrossRefPubMedPubMedCentral

14.

Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O’Rourke DM (2017) SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol 135:487–496. https://doi.org/10.1007/s11060-017-2610-xCrossRefPubMed

15.

Kanumuri R, Kumar Pasupuleti S, Burns SS, Ramdas B, Kapur R (2022) Targeting SHP2 phosphatase in hematological malignancies. Expert Opin Ther Targets 26:319–332. https://doi.org/10.1080/14728222.2022.2066518CrossRefPubMedPubMedCentral

16.

Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M (2019) PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Mol Cancer Res 17:583–593. https://doi.org/10.1158/1541-7786.MCR-18-0777CrossRefPubMed

17.

Kehl KL, Schrag D, Hassett MJ, Uno H (2020) Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. JAMA Netw Open 3:e206976. https://doi.org/10.1001/jamanetworkopen.2020.6976CrossRefPubMedPubMedCentral

18.

Schisterman EF, Cole SR, Ye A, Platt RW (2013) Accuracy loss due to selection bias in cohort studies with left truncation. Paediatr Perinat Epidemiol 27:491–502. https://doi.org/10.1111/ppe.12073CrossRefPubMedPubMedCentral

19.

Heath EI, Lynce F, Xiu J, Ellerbrock A, Reddy SK, Obeid E, Liu SV, Bollig-Fischer A, Separovic D, Vanderwalde A (2018) Racial disparities in the molecular landscape of cancer. Anticancer Res 38:2235–2240. https://doi.org/10.21873/anticanres.12466CrossRefPubMedPubMedCentral

Titel: PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort
verfasst von: Ryohei Otani
Masachika Ikegami
Ryoji Yamada
Hirohisa Yajima
Shinji Kawamura
Sakura Shimizu
Shota Tanaka
Shunsaku Takayanagi
Hirokazu Takami
Tatsuro Yamaguchi
Publikationsdatum: 08.08.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04411-6

Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme

Research

T2-FLAIR mismatch sign correlates with 11C-methionine uptake in lower-grade diffuse gliomas

Case Study

Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis

Open Access
Case Study

Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay

Research

Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience

Case Study

Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis

Open Access
Research

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

„Wir wollen die Bedeutung von Gen- und Umwelteinflüssen besser verstehen“

Bipolare Störung
Interview

Eine Mutation in einem einzelnen Gen kann bei Mäusen eine Art Bipolarstörung auslösen. PD Dr. Jan Deussing vom Max-Planck-Institut für Psychiatrie in München sieht in solchen Tiermodellen eine Möglichkeit, den Ursachen der Erkrankung auf den Grund zu gehen.

Suizidassistenz erhöht Suizidzahlen: Aktuelle Ergebnisse der geplanten S3-Leitlinie

DGPPN 2024
Kongressbericht

Erstmals wird in Deutschland eine S3-Leitlinie zum Thema Suizidalität erarbeitet. Ziel ist es, die Versorgung in suizidalen Krisen durch einheitliche Standards zu verbessern. Erste Ergebnisse der bisherigen Leitlinienarbeit wurden auf dem DGPPN-Kongress vorgestellt.

Kaum Vorteile durch intraarterielle Lyse während Thrombektomie

17.01.2025
Ischämischer Schlaganfall
Nachrichten

Nach der Thrombektomie kleinere Fragmente über eine intraarterielle Lyse auflösen – dies könnte die Schlaganfalltherapie verbessern. Zwei aktuelle Studien ergeben für die periprozedurale Lyse jedoch keine großen Vorteile. Die Frage, wie viel sie nützt, bleibt weiter offen.

Nasenstimulation lindert chronische Migräne

16.01.2025
Chronische Migräne
Nachrichten

Wird die Naseninnenseite durch Vibrationen stimuliert, kann dies offenbar die Zahl der Migränetage von Menschen mit chronischer Migräne deutlich senken. Darauf deuten die Resultate einer randomisiert-kontrollierten deutsch-finnischen Untersuchung.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort